Jinmei Liu

Union Hospital — China

Medicine · Health Sciences

11h-index818citations33works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pain Management and Opioid Use(5), Pharmacological Effects and Toxicity Studies(4), Glioma Diagnosis and Treatment(3), Cancer Immunotherapy and Biomarkers(3), Advanced Sensor and Energy Harvesting Materials(3)

Publications31 total

Analysis of TORCH screening and prenatal risk assessment for childbearing-age women in different regions of China
Journal of Health Population and Nutrition·2025· 1 citedOpen Access
Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis
Frontiers in Pharmacology·2025· 5 citedOpen Access
Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents—A Pharmacovigilance Study Based on the FAERS Database
Journal of Clinical Medicine·2025Open Access
Mitigating public hygiene anxiety in waste material applications: Development of an antibacterial and high performance triboelectric nanogenerator from recycled PET
Nano Energy·2024· 14 cited
The hemostatic activity and Mechanistic roles of glucosyloxybenzyl 2-isobutylmalate extract (BSCE) from Bletilla striata (Thunb.) Rchb.f. in Inhibiting pulmonary hemorrhage
Heliyon·2024· 3 citedOpen Access
Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database
Frontiers in Pharmacology·2024· 7 citedOpen Access
The safety and economic evaluation of bevacizumab and PD-1 inhibitors for advanced non- squamous NSCLC: a multicenter observational study in China
2024Open Access
Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
Frontiers in Pharmacology·2024· 9 citedOpen Access
The regulation and its application of the charge decay rate in triboelectric nanogenerator
Nanotechnology·2024· 4 cited
Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway
Pharmacological Research·2024· 14 citedOpen Access
Opioid Nonadherence Risk Prediction of Patients with Cancer‐Related Pain Based on Five Machine Learning Algorithms
Pain Research and Management·2024· 1 citedOpen Access
Quality Evaluation of Banlangen Granule based on Bioassays ofAnti-influenzal and Anti-inflammatory Effects
Current Pharmaceutical Analysis·2024
Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma
Intelligent Pharmacy·2023Open Access
Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
EClinicalMedicine·2023Open Access
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
Acta Pharmaceutica Sinica B·2023· 10 citedOpen Access
Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022)
Journal of Clinical Medicine·2023· 22 citedOpen Access
Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
EClinicalMedicine·2022· 27 citedOpen Access
Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer
Frontiers in Pharmacology·2022· 21 citedOpen Access
Genetic and Clinical Factors Associated with Opioid Response in Chinese Han Patients with Cancer Pain: An Exploratory Cross-Sectional Study
Pain and Therapy·2022· 6 citedOpen Access
Application of Quality Control Circle Activity in Improving Effectiveness of Drug Intervention in Lung Cancer Patients with Moderate to Severe Pain
Current Medical Science·2021· 5 cited
page 1 of 2Next →

Frequent Co-authors

Shijun Li(10), Zhiwen Fu(9), Chen Shi(6), Cong Wang(5), Juan Luo(5), Jiyi Xie(5), Shijun Li(5), Jianli Hu(4), Xu Chen(4), Changdong Diao(4), Qi Yuan(4), Shi Chen(3), Shi Chen(3), Yu Zhang(3), Hanxiang Wang(3), Yu Zhang(3), Huiping Hu(3), Ruxu You(3), Haixia Zhu(3), Yu Zhang(2)